Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotech company, will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Robert Bitterman will present on the company's INTASYL siRNA gene silencing technology, which aims to enhance immune cells' ability to kill tumor cells.

The presentation will cover:

• INTASYL technology overview
• Associated patents and intellectual property
• Ongoing Phase 1b clinical trial of PH-762, Phio's lead INTASYL compound

Phio's presentation will be streamed online starting September 9th at 7:00 AM ET. The management team will also be available for one-on-one meetings during the conference.

Conference to be held in New York City September 9-11th

Marlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that its President and CEO, Robert Bitterman, will be attending and presenting at the H.C. Wainwright 26^th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City, NY.

Mr. Bitterman will discuss the company's proprietary INTASYL technology, the patents and IP associated with INTASYL, and the on-going Phase 1b clinical trial of its lead INTASYL compound, PH-762.

The company's presentation will be streamed here as of Monday, September 9th at 7:00 AM ET. Phio's management team will be available at the conference for one-on-one meetings September 9-11, 2024.

For additional information, visit the Company's website, www.phiopharma.com.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary technology, INTASYL, precisely silences virtually any gene in the human genome. In addition to targeting solid tumors, INTASYL can effectively enhance applications in adoptive cell therapy.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs, Phio Pharmaceuticals Corp.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221946

FAQ

When and where is Phio Pharmaceuticals presenting at the H.C. Wainwright conference?

Phio Pharmaceuticals (NASDAQ: PHIO) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

What will Phio Pharmaceuticals discuss in their presentation?

Phio Pharmaceuticals will discuss their proprietary INTASYL siRNA gene silencing technology, associated patents and intellectual property, and the ongoing Phase 1b clinical trial of their lead compound, PH-762.

How can investors access Phio Pharmaceuticals' presentation at the conference?

Phio Pharmaceuticals' presentation will be streamed online starting Monday, September 9th, 2024, at 7:00 AM ET. The stream link will be available on the company's website.

What is the main focus of Phio Pharmaceuticals' INTASYL technology?

Phio Pharmaceuticals' INTASYL technology is designed to make immune cells more effective in killing tumor cells, potentially enhancing cancer treatment outcomes.